Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy
Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy
Not yet recruiting · NCT03345134 · Registry updated 2017-11-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy | Endoscopic Surgical Procedure; High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma; Transitional Epithelial Cells | Not yet recruiting | Phase 2 | 2017-11-17 | NCT03345134 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| Shaheen Alanee | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Shaheen Alanee, MD, MPH, MBA | Detroit | United States | 1 |